1
|
Gupta U, Saren BN, Khaparkhuntikar K, Madan J, Singh PK. Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer. J Control Release 2022; 348:1089-1115. [PMID: 35640765 DOI: 10.1016/j.jconrel.2022.05.034] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 05/18/2022] [Accepted: 05/21/2022] [Indexed: 11/30/2022]
Abstract
Breast cancer (BC) is the most extensively accounted malignancy among the women across the globe and is treatable in 70-80% of patients with early-stage, non-metastatic cancer. The current available therapies have been found to be less effective to treat distant organ metastases and advanced breast cancers. The clinical efficacy hugely suffers from chemoresistance, non-specific toxicity, relapse and other associated adverse effects. Furthermore, lack of controlled delivery and effective temporospatial presence of chemotherapeutics has resulted in suboptimal therapeutic response. Nanotechnology based approaches have been widely used over the period as they are nanometric, offer controlled and site-specific drug release along with reduced toxicity, improved half-life, and stability. Lipid-based nanoplatforms have grabbed a tremendous attention for delivering cancer therapeutics as they are cost-effective, scalable and provide better entrapment efficiency. In this review, all the promising applications of lipid-engineered nanotechnological tools for breast cancer will be summarized and discussed. Subsequently, BC therapy achieved with the aid of chemotherapeutics, phytomedicine, genes, peptides, photosensitizers, diagnostic and immunogenic agents etc. will be reviewed and discussed. This review gives tabular information on all the results obtained pertaining to the physicochemical properties of the lipidic nanocarrier, in vitro studies conferring to mechanistic drug release profile, cell viability, cellular apoptosis and in vivo studies referring to cellular internalisation, reduction of tumor volume, PK-PD profile, bioavailability achieved and anti-tumor activity in detail. It also gives complete information on the most relevant clinical trials done on lipidic nanoplatforms over two decades in tabular form. The review highlights the current status and future prospects of lipidic nanoplatforms with streamlined focus on cancer nanotherapeutics.
Collapse
Affiliation(s)
- Ujala Gupta
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India
| | - Brojendra Nath Saren
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India
| | - Kedar Khaparkhuntikar
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India
| | - Jitender Madan
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India
| | - Pankaj Kumar Singh
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
| |
Collapse
|
2
|
A quality by design (QbD) approach in pharmaceutical development of lipid-based nanosystems: A systematic review. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103207] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-κB signaling and autophagy. Biomed Pharmacother 2021; 145:112122. [PMID: 34489150 DOI: 10.1016/j.biopha.2021.112122] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 08/20/2021] [Accepted: 08/24/2021] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVE Berberine (BBR) is a known alkaloid that has verified its protective effects against ischemia/reperfusion (I/RN) lesion in multiple organs but its poor oral bioavailability limited its use. Despite the previous works, its possible impact on the warm hepatic I/RN-induced lesion is not clear. Accordingly, a nanostructured lipid carrier of BBR (NLC BBR) was developed for enhancing its efficiency and to inspect its protective mechanistic against warm hepatic I/RN. METHODS NLC BBR formula was evaluated pharmaceutically. Wistar rats were orally pre-treated with either BBR or NLC BBR (100 mg/kg) for 2 weeks followed by hepatic I/RN (30 min/24 h). Biochemical, ELISA, qPCR, western blot, histopathological, and immunohistochemical studies were performed. KEY FINDINGS Optimized NLC BBR was prepared with a particle size of 130 ± 8.3 nm. NLC BBR divulged its aptitude to safeguard the hepatic tissues partly due to anti-inflammatory capacity through downsizing the HMGB1/TLR4/NF-κB trajectory with concomitant rebating of TNF-α, iNOS, COX-2, and MPO content. Furthermore, NLC BBR antiapoptotic trait was confirmed by boosting the prosurvival protein (Bcl-2) and cutting down the pro-apoptotic marker (Bax). Moreover, its antioxidant nature was confirmed by TAC uplifting besides MDA subsiding. On the other hand, NLC BBR action embroiled autophagy flux spiking merit exemplified in Beclin-1 and LC3-II enhancement. Finally, NLC BBR administration ascertained its hepatocyte guarding action by recovering the histopathological ailment and diminishing serum transaminases. CONCLUSION NLC BBR purveyed reasonable shielding mechanisms and subsided incidents contemporaneous to warm hepatic I/RN lesion in part, by moderating HMGB1/TLR4/NF-κB inflammatory signaling, autophagy, and apoptosis.
Collapse
|
4
|
Chaturvedi S, Verma A, Saharan VA. Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement. Adv Pharm Bull 2020; 10:524-541. [PMID: 33072532 PMCID: PMC7539309 DOI: 10.34172/apb.2020.064] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 02/08/2020] [Accepted: 02/10/2020] [Indexed: 12/12/2022] Open
Abstract
In the treatment of cancer, chemotherapy plays an important role though the efficacy of anti-cancer drug administered orally is limited, due to their poor solubility in physiological medium, inability to cross biological membrane, high Para-glycoprotein (P-gp) mediated drug efflux, and pre-systemic metabolism. These all factors cumulatively reduce drug exposure at the target site leading to multidrug resistance (MDR). Lipid based carriers systems has been explored to overcome solubility and permeability related issues of anti-cancer drugs. The lipid based formulations have also been reported to circumvent the effect of P-gp and CYP3A4. Further long chain triglycerides (LCT) has shown their ability to access Lymphatic route over Medium Chain Triglycerides, as the former has been extensively used for targeting anti-cancer drugs at proliferating cells through lymphatic route. Therefore this review tries to reflect the usefulness of lipid based drug carriers systems (viz. liposome, solid lipid nanoparticle, nano-lipid carriers, self-emulsifying, lipidic pro-drugs) in targeting lymphatic system and overcoming issues related to solubility and permeability of anti-cancer drugs. Moreover, we have also tried to reflect how critically lipid based carriers are important in maximizing therapeutic safety and efficacy of anti-cancer drugs.
Collapse
Affiliation(s)
- Shashank Chaturvedi
- Department of Pharmaceutics, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
| | - Anurag Verma
- Department of Pharmaceutics, School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, India
| | - Vikas Anand Saharan
- Department of Pharmaceutics, School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Dehradun, Uttarakhand, India
| |
Collapse
|
5
|
Monteiro LOF, Fernandes RS, Castro L, Reis D, Cassali GD, Evangelista F, Loures C, Sabino AP, Cardoso V, Oliveira MC, Branco de Barros A, Leite EA. Paclitaxel-Loaded Folate-Coated pH-Sensitive Liposomes Enhance Cellular Uptake and Antitumor Activity. Mol Pharm 2019; 16:3477-3488. [DOI: 10.1021/acs.molpharmaceut.9b00329] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
6
|
Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 2018; 133:285-308. [DOI: 10.1016/j.ejpb.2018.10.017] [Citation(s) in RCA: 199] [Impact Index Per Article: 33.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 10/17/2018] [Accepted: 10/22/2018] [Indexed: 12/11/2022]
|
7
|
B. Shekhawat P, B. Pokharkar V. Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta Pharm Sin B 2017; 7:260-280. [PMID: 28540164 PMCID: PMC5430883 DOI: 10.1016/j.apsb.2016.09.005] [Citation(s) in RCA: 93] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 09/06/2016] [Accepted: 09/21/2016] [Indexed: 11/10/2022] Open
Abstract
Oral drug absorption is a process influenced by the physicochemical and biopharmaceutical properties of the drug and its inter-relationship with the gastrointestinal tract. Drug solubility, dissolution and permeability across intestinal barrier are the key parameters controlling absorption. This review provides an overview of the factors that affect drug absorption and the classification of a drug on the basis of solubility and permeability. The biopharmaceutical classification system (BCS) was introduced in early 90׳s and is a regulatory tool used to predict bioavailability problems associated with a new entity, thereby helping in the development of a drug product. Strategies to combat solubility and permeability issues are also discussed.
Collapse
Key Words
- ABC, ATP-binding cassette
- AP, absorption potential
- API, active pharmaceutical ingredient
- ATP, adenosine triphosphate
- AZT, azidothymidine
- BA/BE, bioavailability/bioequivalence
- BCRP, breast cancer resistance protein
- BCS
- BCS, biopharmaceutical classification system
- BDDS, biopharmaceutical drug disposition system
- BSP, bromosulfophthalein
- CD, cyclodextrin
- CDER, Centre for Drug Evaluation and Research
- CNT, Na+-dependent concentrative transporter
- CNT, concentrative nucleoside transporter
- CYP, cytochrome P450
- D:S, dose:solubility
- E217G, estradiol 17β-glucuronide
- EMEA, European Medicines Agency
- ENT, equilibrative nucleoside transporter
- FATP, fatty acid transporter protein
- FDA, U.S. Food and Drug Administration
- FIP, International Pharmaceutical Federation
- FaSSIF, fasted state simulated intestinal fluid
- Factors affecting absorption
- FeSSIF, fed state simulated intestinal fluid
- Formulation strategies
- GIS, gastrointestinal simulator
- GIT, gastrointestinal tract
- GITA, gastrointestinal transit and absorption
- GLUT, sodium-independent facilitated diffusion transporter
- GRAS, generally recognized as safe
- HIV, human immunodeficiency disease
- HPC-SL, LBDDS, lipid based drug delivery system
- HUGO, Human Genome Organization
- ICH, International Council of Harmonization
- IDR, intrinsic dissolution rate
- IR, immediate release
- ISBT, sodium dependent bile salt transporter
- MCT, monocarboxylate transporter
- MPP, 1-methyl-4-phenylpyridinium
- MRP, multidrug resistance associated protein
- NLC, nanostructured lipid carrier
- NME, new molecular entity
- NTCP, sodium-dependent taurocholate co-transporting polypeptide
- OAT, organic anion transporter
- OATP, organic anion transporting polypeptide
- OCT, organic cationic transporter
- OCTN, organic cationic/carnitine transporter
- OMM, ordered mesoporous material
- P-gp, P-glycoprotein
- PAH, p-aminohippurate
- PAMPA, parallel artificial membrane permeability assay
- PEG, polyethylene glycol
- PEI, polyethyleneimine
- PEPT, peptide transporter
- PGA, polyglycolic acid
- PLA, poly(lactic acid)
- PLGA, poly-d,l-lactide-co-glycoside
- PMAT, plasma membrane monoamine transport
- PSA, polar surface area
- PVDF, polyvinylidene difluoride
- Papp, apparent permeability
- Peff, effective permeability
- Permeability
- Psi, porous silicon
- RFC, reduced folate transporter
- SDS, sodium dodecyl sulphate
- SGLT, sodium dependent secondary active transporter
- SIF, simulated intestinal fluid
- SLC, solute carrier
- SLCO, solute carrier organic anion
- SLN, solid lipid nanoparticles
- SMVT, sodium dependent multivitamin transporter
- SPIP, single pass intestinal perfusion
- SUPAC, scale-up and post approval changes
- SVCT, sodium-dependent vitamin C transporter
- Solubility
- TEOS, tetraethylortho silicate
- UWL, unstirred water layer
- VDAD, volume to dissolve applied dose
- WHO, World Health Organization
- pMMA, polymethyl methacrylate
- vit. E TPGS, vitamin E tocopherol polyethylene glycol succinate
Collapse
|
8
|
ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. J Control Release 2017; 249:103-110. [DOI: 10.1016/j.jconrel.2017.01.039] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 01/25/2017] [Accepted: 01/27/2017] [Indexed: 11/20/2022]
|
9
|
Wang F, Li L, Liu B, Chen Z, Li C. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer. Biomed Pharmacother 2017; 86:595-604. [DOI: 10.1016/j.biopha.2016.12.041] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 12/01/2016] [Accepted: 12/09/2016] [Indexed: 12/14/2022] Open
|
10
|
Cavaco MC, Pereira C, Kreutzer B, Gouveia LF, Silva-Lima B, Brito AM, Videira M. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. Eur J Pharm Biopharm 2017; 110:76-84. [DOI: 10.1016/j.ejpb.2016.10.024] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 09/21/2016] [Accepted: 10/30/2016] [Indexed: 01/10/2023]
|
11
|
Self-assembly PEGylation assists SLN-paclitaxel delivery inducing cancer cell apoptosis upon internalization. Int J Pharm 2016; 501:180-9. [DOI: 10.1016/j.ijpharm.2016.01.075] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Revised: 01/25/2016] [Accepted: 01/28/2016] [Indexed: 12/11/2022]
|
12
|
Barbosa MV, Monteiro LOF, Carneiro G, Malagutti AR, Vilela JMC, Andrade MS, Oliveira MC, Carvalho-Junior AD, Leite EA. Experimental design of a liposomal lipid system: A potential strategy for paclitaxel-based breast cancer treatment. Colloids Surf B Biointerfaces 2015; 136:553-61. [PMID: 26454545 DOI: 10.1016/j.colsurfb.2015.09.055] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 09/10/2015] [Accepted: 09/27/2015] [Indexed: 10/23/2022]
Abstract
Paclitaxel (PTX) is widely used as a first-line treatment for patients with metastatic breast cancer; however, its poor water solubility represents a major challenge for parenteral administration. The encapsulation of the PTX in drug-delivery systems with high affinity for tumor sites could improve the uptake and increase its therapeutic efficacy. In this work, long-circulating and pH-sensitive PEG-coated (SpHL-PTX) and PEG-folate-coated liposomes containing PTX (SpHL-FT-PTX) were prepared, and the physicochemical properties and in vitro cytotoxic activity were evaluated. Both formulations presented adequate physicochemical properties, including a mean diameter smaller than 200 nm, zeta potential values near the neutral range, and an encapsulation percentage higher than 93%. Moreover, SpHL-FT-PTX showed a good stability after storage for 100 days at 4 °C. The viability studies on breast cancer cell lines (MDA-MB-231 and MCF-7) demonstrated cytotoxic activity more pronounced for SpHL-FT-PTX than for SpHL-PTX or free drug for both tumor cell lines. This activity was reduced to a rate comparable to SpHL-PTX when the cells were previously treated with folic acid in order to saturate the receptors. In contrast, in the normal cell line (L929), cell viability was decreased only by free or liposomal PTX in the highest concentrations. A significantly higher selectivity index was obtained after SpHL-FT-PTX treatment compared to SpHL-PTX and free PTX. Therefore, the results of the present work suggest that SpHL-FT-PTX can be a promising formulation for the treatment of metastatic breast cancer.
Collapse
Affiliation(s)
- Marcos V Barbosa
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Faculdade de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Rodovia MGT 367-Km 583, 5000, 39100-000, Diamantina, Minas Gerais, Brazil
| | - Liziane O F Monteiro
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Guilherme Carneiro
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Faculdade de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Rodovia MGT 367-Km 583, 5000, 39100-000, Diamantina, Minas Gerais, Brazil
| | - Andréa R Malagutti
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Faculdade de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Rodovia MGT 367-Km 583, 5000, 39100-000, Diamantina, Minas Gerais, Brazil
| | - José M C Vilela
- Centro de Tecnologia SENAI-CETEC, Avenida José Cândido da Silveira, 2000, Belo Horizonte, MG 31170-000, Brazil
| | - Margareth S Andrade
- Centro de Tecnologia SENAI-CETEC, Avenida José Cândido da Silveira, 2000, Belo Horizonte, MG 31170-000, Brazil
| | - Mônica C Oliveira
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901 Belo Horizonte, Minas Gerais, Brazil
| | - Alvaro D Carvalho-Junior
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Faculdade de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Rodovia MGT 367-Km 583, 5000, 39100-000, Diamantina, Minas Gerais, Brazil
| | - Elaine A Leite
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Faculdade de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Rodovia MGT 367-Km 583, 5000, 39100-000, Diamantina, Minas Gerais, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
| |
Collapse
|
13
|
Novel applications of ubiquinone biopolymer nanocarriers for preventive and regenerative therapeutics: The Saccharomyces cerevisiae paradigm. Int J Pharm 2015; 478:416-425. [DOI: 10.1016/j.ijpharm.2014.11.034] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 11/11/2014] [Accepted: 11/13/2014] [Indexed: 01/30/2023]
|
14
|
Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm 2014; 11:1239-49. [PMID: 24621456 PMCID: PMC3993949 DOI: 10.1021/mp4006968] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
![]()
Docetaxel
(DCX) is a second generation taxane. It is approved by
the U.S. Food and Drug Administration for the treatment of various
types of cancer, including breast, non-small cell lung, and head and
neck cancers. However, side effects, including those related to Tween
80, an excipient in current DCX formulations, can be severe. In the
present study, we developed a novel solid lipid nanoparticle (SLN)
composition of DCX. Trimyristin was selected from a list of high melting
point triglycerides as the core lipid component of the SLNs, based
on the rate at which the DCX was released from the SLNs and the stability
of the SLNs. The trimyristin-based, PEGylated DCX-incorporated SLNs
(DCX-SLNs) showed significantly higher cytotoxicity against various
human and murine cancer cells in culture, as compared to DCX solubilized
in a Tween 80/ethanol solution. Moreover, in a mouse model with pre-established
tumors, the new DCX-SLNs were significantly more effective than DCX
solubilized in a Tween 80/ethanol solution in inhibiting tumor growth
without toxicity, likely because the DCX-SLNs increased the concentration
of DCX in tumor tissues, but decreased the levels of DCX in major
organs such as liver, spleen, heart, lung, and kidney. DCX-incorporated
SLNs prepared with one or more high-melting point triglycerides may
represent an improved DCX formulation.
Collapse
Affiliation(s)
- Youssef Wahib Naguib
- Pharmaceutics Division, College of Pharmacy, and ‡Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin , Austin, Texas 78712 United States
| | | | | | | | | | | |
Collapse
|